Important Notice for Intellia Therapeutics Shareholders
The Gross Law Firm is reaching out to shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA). This notice serves as a reminder regarding the opportunity for shareholders who purchased shares of NTLA to potentially be appointed as lead plaintiffs in a significant class action lawsuit.
How to Get Involved
If you acquired shares within the designated class period, it’s important to engage with the legal firm for guidance on your rights and options. Your appointment as lead plaintiff is not necessary to be part of any recovery related to the case.
Details of the Class Period
Investors who acquired shares between July 30, 2024 and January 8, 2025 are encouraged to make their voices heard. This class action concerns the disclosure of critical information by Intellia Therapeutics regarding their Phase 1/2 study of NTLA-3001.
Overview of Allegations Against Intellia
Legal allegations state that the company provided investors with misleading information about the progress and viability of NTLA-3001, which was under evaluation for treating alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Investors were assured of a timeline for the study that, in hindsight, appears to have been optimistic.
Emergence of the Truth
Significant revelations came to light on January 9, 2025, when Intellia issued a press release detailing an organizational restructuring. This included halting all research on NTLA-3001 and reducing its workforce. Such announcements had an immediate impact on the company’s stock price, which dropped from $12.02 to $10.20 shortly after the news broke.
Key Deadline to Remember
All affected shareholders should be aware that the deadline to submit claims is set for April 14, 2025. It’s critical for interested parties to take prompt action.
Next Steps for Concerned Shareholders
By registering as a shareholder who purchased NTLA shares during the specified period, you’ll gain access to continuous updates regarding the case’s progress. This service ensures that you're well-informed and aware of developments as they unfold. Notably, there are no costs associated with participating as a plaintiff.
About The Gross Law Firm
The Gross Law Firm strives to uphold the rights of investors who have experienced losses due to corporate misconduct. This firm focuses on advocating for investors impacted by misleading statements that inflate a company's stock price unfairly. The commitment to corporate responsibility is central to their mission.
Contact Information
For further inquiries or clarifications, contact The Gross Law Firm at:
The Gross Law Firm
15 West 38th Street, 12th Floor
New York, NY 10018
Phone: (646) 453-8903
Frequently Asked Questions
What is the lead plaintiff deadline for Intellia Therapeutics?
The lead plaintiff deadline is April 14, 2025, for shareholders who wish to get involved in the class action lawsuit.
Who can participate in the class action?
Shareholders who purchased shares of NTLA during the class period from July 30, 2024, to January 8, 2025, are eligible to participate.
Do I need to be a lead plaintiff to recover losses?
No, you do not need to be appointed as a lead plaintiff to be part of the recovery process.
How will I stay updated about the case?
Once you register, you will be enrolled in a monitoring system that will provide regular updates on the case's progress.
What is the focus of the lawsuit?
The lawsuit addresses misleading information provided by Intellia regarding its NTLA-3001 study and subsequent operational decisions that affected stock prices.
